Peptide Degradation After Reconstitution

Scope: How quickly do reconstituted peptides degrade? How much depends on temperature, how much on the peptide? Focus on retatrutide; semaglutide and tirzepatide used as reference compounds with far more public data.

Last updated: 2026-05-23
Status: Revised v2 after independent fact-checks by a Claude subagent and codex CLI. Both reviewers converged on the same critical errors (now corrected); remaining caveats are explicit below.

Confidence tiers: C1 primary (FDA label, peer-reviewed paper) / C2 credible secondary (review, patent, vendor citing labels) / C3 inferred (analogy, Arrhenius extrapolation — reasoning shown) / C4 anecdotal (Reddit/forum) / C5 unknown.

Important framing caveat (applies to whole document): FDA / EMA label numbers in this document are for optimized commercial product (buffered formulation, controlled headspace, sealed device, full ICH stability dossier behind the label). Grey-market product reconstituted in bacteriostatic water with no buffer, no inert headspace, no light protection, no QC data is not equivalent. Treat label windows as the upper bound for what an analogous peptide can tolerate in a well-formulated product, not as a number directly transferable to a grey-market vial. Discount accordingly.

TL;DR

How much does degradation depend on temperature?

A lot for chemical pathways, less predictably for physical pathways. Chemical degradation (deamidation, oxidation, hydrolysis) of typical peptides roughly doubles per +10 °C between 4 °C and ~30 °C (Q10 ≈ 2; activation energy ~13–20 kcal/mol). [C1, Stratton et al. 2001 PMID 11745773, model peptide VYPNGA at pH 9; general peptide literature] However: for lipidated GLP-1 analogues (semaglutide, tirzepatide, retatrutide), aggregation/micelle formation is often the rate-limiting failure mode in solution, and aggregation kinetics are non-Arrhenius — Q10 extrapolation can substantially mis-predict shelf life in either direction near the peptide's pI. [C2, Wang 1999]

Empirically anchored:
- Refrigerator (2–8 °C) reconstituted in BAC water: ~28 days conservative, 4–6 weeks defensible by analogy to commercial products, 6–12 weeks "many biohackers do it without obvious issue" but with no quantitative validation.
- Room temperature, commercial pre-filled product (different chemistry from grey-market reconstitution; do not transfer numbers directly): 21 days for tirzepatide pens, 56 days for Ozempic (multi-dose), 28 days total RT allowance for Wegovy (single-dose pen) (all C1 from labels). The Wegovy/Ozempic difference is regulatory/packaging-driven (single-dose vs multi-dose), not chemistry.
- 37 °C / body temp: no published data; Q10 extrapolation suggests ~days for chemical degradation, plus aggregation can accelerate non-linearly. Treat any multi-hour body-temp exposure as compromised.
- Freezer for reconstituted solution: explicitly contraindicated by Lilly and Novo Nordisk for all commercial products. Mechanism: ice damage + freeze-concentration of solute above CMC drives irreversible aggregation. Lyophilized (dry powder) freezes fine.
- ≥80 °C: matter of hours.

How much does it depend on the peptide?

A lot. Sequence and structure variation moves shelf-lives by 10×–100× even within "similar" peptides. Specifically:
- Deamidation hot spots (Asn-Gly, Asn-Ser, Asn-His, Asn-Asn, Asn-Ala dipeptide motifs): half-life can be as short as ~24 h at pH 7.4 / 37 °C, vs. ~500 d for Asn-Pro. [C1, Robinson & Robinson PNAS 2001]
- Oxidation-prone residues (Met, free Cys, Trp): present → vulnerability if not deoxygenated/chelated.
- Lipidation (fatty diacid attached to a lysine — semaglutide, tirzepatide, retatrutide): stabilizes vs. proteolysis in vivo, but promotes aggregation/micelle formation in solution. Most consequential effect on shelf-life.
- Sequence length / interface complexity: retatrutide is 39 aa serving three receptors → fewer free positions for stabilizing substitutions vs. semaglutide's 31 aa serving one.
- Lyophilized vs. aqueous: dry powder is ~100× more stable than solution at the same temperature.
- Aib² (α-aminoisobutyric acid at position 2): present in semaglutide, tirzepatide, retatrutide — disfavors diketopiperazine N-terminal degradation by restricting backbone geometry. The GLP-1 triple-agonist class is engineered to avoid the worst small-peptide failure modes.

Bottom line for retatrutide specifically

• No peer-reviewed stability data exists for retatrutide as of May 2026 (no PubMed hits on retatrutide / LY3437943 forced-degradation, accelerated-stability, or HPLC-purity-vs-time studies). [C1 negative finding]
• Best estimate (by analogy to semaglutide/tirzepatide): 28 days at 4 °C is defensible; 4–6 weeks is plausible by analogy; 6–8 weeks is optimistic vendor marketing without empirical support. [C3]
• Reasons to discount vs. semaglutide's commercial 56-day in-use window: (a) grey-market BAC-water reconstitution is unbuffered (~pH 5–6, near isoelectric pH — the worst pH for lipidated GLP-1 stability per Malgave 2025 on semaglutide); (b) grey-market vials have no inert headspace, increasing Met oxidation risk; (c) higher initial impurity from non-Lilly synthesis can catalyze further degradation; (d) 39 aa vs 31 aa = more positions susceptible to degradation; (e) commercial product is in optimized phosphate buffer, not raw BAC water. (Note: the "tirzepatide is more base-labile than semaglutide" claim sometimes used to support this is unsupported by the published forced-degradation data when exposure times are matched — see §2.3.)
• The single mechanistically strongest rule: do not freeze reconstituted retatrutide. Both Lilly and Novo contraindicate freezing aqueous formulations of related lipidated peptides. [C1] A widely-cited third-party assay (Janoshik, paraphrased through GLP1Forum) reportedly shows ~14% loss frozen vs. 3–5% refrigerated at 45 days for retatrutide, but this trace to a single forum source and is not independently verifiable. [C4, not C3]

1. Temperature dependence — the quantitative picture

1.1 Arrhenius / Q10 framework

Chemical degradation rates follow Arrhenius: k = A·exp(−Ea/RT). For peptides, the temperature dependence is captured by Q10 (rate increase per +10 °C):

Sources: Stratton et al. J Pharm Sci 2001 — VYPNGA model hexapeptide deamidation, Ea ≈ 13.3 kcal/mol, at pH 9 (caveat: this is alkaline, not directly applicable to a pH ~7 storage formulation, but is the most-cited literature anchor for peptide deamidation Ea) [C1, PMID 11745773]; Waterman et al. MedChemComm 2011 — distribution of pharmaceutical Ea [C1, https://pubs.rsc.org/en/content/articlelanding/2011/md/c0md00214c]; oxytocin Pharm Res — Ea 28 kcal/mol at pH 4.5 [C1, https://link.springer.com/article/10.1007/s11095-009-9878-2]; ICH Q1A(R2) accelerated-stability guideline.

Practical translation, assuming Q10 ≈ 2 (deamidation-dominated peptide; lower bound) — if rate at 4 °C is 1%/week, then:

Caveats — read before using this table:
1. The 1%/week baseline at 4 °C is itself uncertain for GLP-1 analogues in BAC water — could be 0.3% or 3% — but the ratios are roughly correct for the chemical (not aggregation) component.
2. Arrhenius/Q10 fails for aggregation. [C2, Wang 1999, https://pubmed.ncbi.nlm.nih.gov/10460913/] Nucleation has a non-Arrhenius lag-then-autocatalytic curve. For lipidated GLP-1 analogues — where aggregation/micelle formation is plausibly the dominant failure mode in solution — applying Q10 to predict shelf life can over- or under-estimate substantially. The table above describes the chemical-degradation component only.
3. The Stratton Ea was measured at pH 9. At storage-relevant pH (5–7), deamidation Ea can differ; Ea also varies by sequence context. The 1.5–3× per 10°C envelope is a rule of thumb, not a guarantee.
4. Ozempic's label allows 56 days at either 2–8 °C or 15–30 °C [C1, https://www.novonordiskmedical.com/product-information/storage-and-stability/glp-1-ras.html]. The same envelope at two temperatures most likely means the regulatory window is set by sterility/preservative requirements, not chemistry — the formulation's chemical stability comfortably exceeds 56 days at refrigerator temperature.

1.2 Real-world anchors from FDA / EMA labels

Apparent contradictions across these labels are not chemical — Wegovy's 28-day RT allowance vs. Ozempic's 56-day multi-dose in-use uses the same molecule. The Wegovy difference is regulatory/packaging: single-use disposable pen with a different excipient and device profile, not a stability-driven cap. The 28-day compounding BUD is set by benzyl alcohol's microbial-preservation window and USP <797> sterility rules, not by potency loss.

Critical translation caveat: None of these label numbers apply directly to grey-market reconstituted product. They are for sealed, buffered, preservative-containing, QC-released commercial formulations. The grey-market case (lyophilized powder of unknown purity + BAC water in an unbuffered vial with air headspace) is more vulnerable to oxidation, more prone to pH drift toward the pI, and lacks the device-level protections (sealed cartridge, inert gas, light protection) that make these long windows possible. Treat the label numbers as upper bounds, not targets.

1.3 Freeze-thaw is a separate axis

For lipidated GLP-1 analogues (semaglutide, tirzepatide, retatrutide), freezing the reconstituted aqueous solution is more damaging than refrigerating it — counter to amateur intuition. Mechanism: ice crystal formation disrupts the micellar organization; freeze-concentration of solute in unfrozen channels pushes local concentration well above the critical micelle concentration (CMC ≈ 0.06 wt% for semaglutide [C1, Biomacromolecules 2025]); the resulting aggregates do not redisperse on thaw.

• Lilly explicitly contraindicates freezing for Mounjaro/Zepbound: "Do not freeze the Pen; if the Pen has been frozen, throw the Pen away." [C1]
• Novo Nordisk same for Ozempic/Wegovy. [C1]
• Janoshik (Czech third-party peptide lab): reportedly ~14% degradation at 45 days frozen vs. 3–5% refrigerated, for reconstituted retatrutide. Caveat: this number is paraphrased through a single GLP1Forum thread; the underlying HPLC data, sample size, and methodology are not independently verifiable. Treat as C4 / community lore, not C3. [https://glp1forum.com/threads/can-reconstituted-reta-be-re-aliqouted-and-frozen.5844/]

Lyophilized (dry powder) freezing is a separate story — fine at −20 °C (12–24 mo), better at −80 °C (3+ yr). [C2, vendor data]

2. Peptide-specific dependence — what makes one peptide more stable than another

2.1 Major degradation pathways

2.2 What this means for ranking peptides

Going from most stable to least stable (rough community/literature consensus):

• Most stable: Cyclic peptides; small simple sequences (GHK-Cu, KPV); thymosin α-1 family.
• Engineered for stability: Sema/tirz/reta — Aib² (blocks DKP), lipidated to extend half-life and stabilize against proteolysis, formulated by Lilly/Novo at pH 7+ to avoid pI region.
• Less stable: Long, flexible, multi-receptor peptides with Asn-Gly motifs; peptides with free Met or Trp; non-buffered grey-market formulations.
• Notoriously fragile: BPC-157 (community claims of rapid degradation are debated), oxytocin (multiple degradation pathways), free-Cys peptides.

2.3 GLP-1 family specifically

Semaglutide (31 aa, lipidated at Lys26 with C18 diacid):
- Most stable at pH ≥ 7; worst at pH 4.5–5.5 (pI 5.4). [C1, Malgave 2025]
- Forced degradation HPLC: ~14 peaks (acid), ~13 (base), ~18 (oxidation), ~35 (thermal) — Met oxidation + Asn deamidation dominant. [C1, BMC Chemistry 2025]
- Stable for 3 h at 80 °C in optimized buffer — genuinely tough. [C1, Malgave 2025]
- Forms ~2.5 nm micelles in aqueous solution over ~40 days at 4 °C; aggregated form retains some bioactivity but ~80% reduction in epithelial permeability. [C1, Biomacromolecules 2025]

Tirzepatide (39 aa, lipidated at Lys20 with C20 diacid):
- BMC Chemistry 2025 forced-degradation reports 18.97% tirz degraded in 0.1 M NaOH, 25 °C, 20 min vs. 13.00% sema in 0.1 M NaOH, 25 °C, 5 min. The exposure times are unequal — per unit time under those forced conditions, semaglutide degrades faster, not slower. The earlier (and widely-circulated) claim that "tirzepatide is more base-labile than semaglutide" derived from these numbers is not supported by the data when time is normalized. [C1, https://pmc.ncbi.nlm.nih.gov/articles/PMC12918740/ — but conclusion in our v1 draft was wrong; corrected here]
- Most oxidation-prone at pH 5 even at 5 °C — acidic excursions are dangerous. [C2, Phenomenex tech note]
- Lilly patent (WO2024006662A1) discloses long-term stability data at 2–8 °C and 25 °C/60% RH in pH 6.5–7.5 phosphate-saline buffer; specific impurity tables are image-only in the disclosed patent and not transcribable. [C1]
- Commercial Mounjaro/Zepbound are pre-filled liquid (not lyophilized) — their in-use label data is the strongest aqueous-stability anchor we have for the family, but applies to optimized buffered formulation, not to BAC-water reconstitution.

Retatrutide (39 aa, lipidated at Lys17 with a fatty diacid; full linker chemistry per Sun et al. 2024 cryo-EM is similar to but not identical to semaglutide's γGlu-OEG-OEG):
- No published forced-degradation, accelerated-stability, or HPLC-purity-vs-time data as of May 2026. [C1 negative]
- Structurally analogous to sema/tirz — same backbone family, similar lipidation strategy. Cryo-EM confirms acylation at Lys17. [C1, Li/Sun et al. Cell Discovery 2024, https://pmc.ncbi.nlm.nih.gov/articles/PMC11255275/]
- Expected to share the pI ≈ 5–6 region, Met oxidation susceptibility, and micelle-formation behavior of its analogues — but this is inferred, not measured.
- Plasma t½ ~6 days (between sema ~7 and tirz ~5) — confirms effective albumin binding, but plasma t½ does NOT predict solution shelf-life (different chemistry: albumin protection in vivo vs. aqueous storage).

3. Retatrutide-specific guidance

3.1 What is known

3.2 Best-inferred shelf life (C3 throughout)

3.3 Reasons reconstituted grey-market retatrutide may be less stable than commercial semaglutide

(These are arguments about the grey-market preparation, not about the molecule itself. The pure peptide chemistry of retatrutide vs. semaglutide is not well-characterized comparatively.)

1. BAC water reconstitution sits at unbuffered ~pH 5–6, near the lipidated GLP-1 pI range. Semaglutide is most unstable at pH 4.5–5.5 [C1, Malgave 2025]; retatrutide likely shares this sensitivity. [C3 by analogy] Commercial Ozempic is at pH ~7.4 in phosphate buffer — this is a real chemistry difference.
2. No inert headspace. Grey-market vials are typically not N₂-purged. Met oxidation is driven by dissolved O₂ + trace metals; refrigeration only modestly slows it. [C2]
3. Grey-market synthesis purity is typically reported at 98–99% vs. pharmaceutical ≥99.5%. Initial impurities can catalyze further degradation (acid impurities lower pH; metal contamination drives oxidation). [C3]
4. More residues (39 vs. 31) — more positions susceptible to deamidation/oxidation in principle.
5. Three-receptor interface constraints — less sequence freedom to optimize stability versus a single-receptor agonist. [C3, speculative]

None of these are quantified for retatrutide specifically. Best-faith estimate: shelf-life somewhat shorter than commercial semaglutide's 56-day pen window, comparable to or slightly worse than tirzepatide's 21-day pen window when adjusted for the unbuffered grey-market formulation.

3.4 Visual indicators

• Cold cloudiness that clears at room temp in ~20 min: NOT degradation. Reversible cold-induced solubility behavior, well-documented for reta. [C3, multiple community threads]
• Non-reversible cloudiness, persistent particles, yellow discoloration, odor: discard.
• Visual clarity does NOT prove potency. Slow chemical degradation (Met oxidation, Asn deamidation) is invisible. A clear vial that "doesn't work anymore" is a documented community failure mode.

4. Practical recommendations

4.1 If using retatrutide (or any GLP-1 analogue) reconstituted in BAC water

Conservative protocol:
- Refrigerate at 2–8 °C immediately after reconstitution.
- Use within 28 days.
- Minimize room-temperature time (handling for injection is fine; overnight is fine; days at RT is not).
- Do not freeze the reconstituted solution.
- Discard if you see persistent (room-temp-stable) cloudiness, particulates, or yellowing.

Reasonable protocol if cost-constrained:
- Same as above, but extend to 6 weeks in the fridge.
- Aliquot the lyophilized powder before reconstitution (single-freeze, no thaw cycles tolerated for lyo).
- Reconstitute only what you'll use in 4–6 weeks.

What NOT to do:
- Freeze the reconstituted solution.
- Leave at >30 °C for extended periods (>24 h).
- Trust visual clarity as a potency check.
- Trust vendor claims of "60+ day reconstituted shelf life" — these are marketing.
- Use a vial that's been through a hot shipping cycle (summer, slow shipping, no ice pack) without acknowledging potential loss.

4.2 Buffer choice

• BAC water (0.9% benzyl alcohol): Default for multi-dose use. Microbially preserves the vial. Does NOT specifically stabilize the peptide.
• Sterile water (no preservative): Theoretically equal chemical stability, but practical sterility window is ~24 h.
• Saline (0.9% NaCl): Roughly equivalent to sterile water. Sometimes preferred in Europe.
• Adding sterile phosphate buffer to raise pH to ~7: Theoretically would extend chemical stability significantly (avoid pI region). No grey-market protocols do this and sterility concerns are real.

4.3 Failure modes to watch for

5. Open questions and data gaps

1. No published Arrhenius Ea for semaglutide aqueous degradation. Malgave's preformulation studies collected the data at 5/25/40/60/80 °C but published only % degradation per condition, not fitted Ea. [C5]
2. No published % degradation/week curves at standard temperatures for any GLP-1 analogue in BAC-water reconstitution.
3. Lilly's tirzepatide and retatrutide formulation patent stability tables are image-only — visible but not transcribable.
4. No 37 °C body-temp data in formal stability studies. Real-world relevance: injection delays, accidental body-warmth exposure.
5. No published forced-degradation study specific to retatrutide.
6. No human PK comparison of retatrutide dosed from vials stored >28 days vs. fresh.
7. Reddit threads for community practice were not directly fetchable from this research environment; community evidence was triangulated via indexed forum sources (primarily GLP1Forum.com). A direct r/retatrutide / r/peptides survey would improve confidence in the distribution-of-practice numbers in §1.2.

6. Source summary

Primary chemistry / pharmaceutics literature

• Robinson & Robinson, PNAS 2001 — deamidation half-lives by sequence [C1]: https://pmc.ncbi.nlm.nih.gov/articles/PMC60067/
• Capasso et al. — Ea ~13.3 kcal/mol for peptide deamidation [C1]: https://www.sciencedirect.com/science/article/abs/pii/S0022354916305147
• Schöneich Pharm Res series — Met oxidation kinetics [C1]: https://link.springer.com/article/10.1023/A:1016240115675
• Manning, Patel & Borchardt — Stability of protein pharmaceuticals [C1/C2]: https://link.springer.com/article/10.1007/s11095-009-0045-6
• Wang W. 1999 — Instability and formulation of liquid protein pharmaceuticals [C2]: https://pubmed.ncbi.nlm.nih.gov/10460913/
• Waterman et al. MedChemComm 2011 — pharmaceutical degradation Ea distribution [C1]: https://pubs.rsc.org/en/content/articlelanding/2011/md/c0md00214c
• ICH Q1A(R2) — accelerated stability guideline.

GLP-1 analogue–specific primary literature

• Malgave et al. J Peptide Science 2025 — semaglutide pH/buffering/temp stability [C1]: https://pubmed.ncbi.nlm.nih.gov/40635175/
• Malgave et al. Eur J Pharm Biopharm 2025 — semaglutide degradation pathways [C1]: https://pubmed.ncbi.nlm.nih.gov/40490042/
• BMC Chemistry 2025 — stability-indicating HPLC for sema and tirz [C1]: https://pmc.ncbi.nlm.nih.gov/articles/PMC12918740/
• Hamley et al. Biomacromolecules 2025 — semaglutide aggregation kinetics [C1]: https://pmc.ncbi.nlm.nih.gov/articles/PMC12152837/
• Sun et al. 2024 — retatrutide cryo-EM structure [C1]: https://pmc.ncbi.nlm.nih.gov/articles/PMC11255275/

Regulatory / manufacturer labels

• Novo Nordisk GLP-1 storage and stability [C1]: https://www.novonordiskmedical.com/product-information/storage-and-stability/glp-1-ras.html
• Eli Lilly Mounjaro IFU [C1]: https://pi.lilly.com/us/mounjaro-us-ifu.pdf
• Eli Lilly Zepbound vial IFU [C1]: https://pi.lilly.com/us/zepbound-vial-us-ifu.pdf
• FDA Zepbound label [C1]: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217806s003lbl.pdf
• FDA Ozempic label [C1]: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209637s020s021lbl.pdf
• EMA Rybelsus assessment [C1]: https://www.ema.europa.eu/en/documents/assessment-report/rybelsus-epar-public-assessment-report_en.pdf

Patents

• WO2024006662A1 — Lilly tirzepatide compositions [C1]: https://patents.google.com/patent/WO2024006662A1/en
• WO2025141472A1 — stable tirzepatide compositions [C1]: https://patents.google.com/patent/WO2025141472A1/en
• CN117903284A — retatrutide synthesis (no formulation data) [C1]: https://patents.google.com/patent/CN117903284A/en

Community / forum evidence (C3/C4)

• GLP1Forum reconstituted reta shelf life: https://glp1forum.com/threads/reconstituted-reta-whats-the-latest-on-shelf-life.8635/
• GLP1Forum Janoshik myths busted: https://glp1forum.com/threads/peptide-myths-busted-janoshik-founder-sets-the-record-straight.5811/
• GLP1Forum freeze vs fridge: https://glp1forum.com/threads/can-reconstituted-reta-be-re-aliqouted-and-frozen.5844/
• GLP1Forum cold cloudiness: https://glp1forum.com/threads/cloudy-reta-a-week-after-reconstitution.11441/
• GLP1Forum "cooked reta": https://glp1forum.com/threads/cooked-reta-and-stop-start.9858/
• GLP3 Planner storage guide [C2]: https://glp3planner.com/resources/retatrutide-storage-stability

Detailed research notes

• semaglutide-stability-notes.md (this directory)
• tirzepatide-stability-notes.md (this directory)
• retatrutide-stability-notes.md (this directory)
• peptide-degradation-chemistry.md (this directory)
• community-shelf-life-notes.md (this directory)

Appendix A — Revision log (v1 → v2)

Independent fact-checks (a Claude subagent and codex CLI) converged on these issues. v2 corrects each:

1. BMC Chemistry 2025 forced-degradation comparison. v1 claimed "tirzepatide more base-labile than semaglutide" from 18.97% (tirz) vs. 13.00% (sema). The exposure times in the source paper are unequal (tirz 20 min, sema 5 min); per unit time, sema actually degrades faster. v2 removes this as a "reason retatrutide may be less stable" and explicitly flags the misread of the source. (Both reviewers flagged this.)
2. Wegovy 28-day window. v1 framed it as "after first use," analogous to Ozempic's 56-day. Wegovy is a single-dose disposable pen — the 28 days is the total RT exposure allowance, not an in-use period. Reframed in §1.2 and TL;DR.
3. Janoshik 14% frozen / 3–5% refrigerated claim was tagged C3 in v1 and used as a load-bearing recommendation. The number traces to a single GLP1Forum thread with no independent verifiability; demoted to C4. The recommendation "don't freeze reconstituted" still stands on Lilly's explicit C1 contraindication and the mechanistic argument (freeze-concentration above CMC), not on Janoshik's number.
4. Capasso citation. The 13.3 kcal/mol Ea is from Stratton et al. 2001 (PMID 11745773) on model peptide VYPNGA at pH 9, not from Capasso. v2 corrects the citation. Also noted that pH 9 limits direct extrapolation to pH 5–7 storage conditions.
5. Aggregation/Arrhenius inconsistency. v1 noted aggregation is non-Arrhenius once in §1.1, then applied Q10 elsewhere. v2 makes this caveat more prominent in TL;DR and §3 — for lipidated GLP-1 analogues, aggregation may dominate failure, and Q10 may not apply.
6. Headspace O₂ / Met oxidation. v1 omitted this. v2 adds it as a "reason grey-market may be less stable" specifically (no N₂ purge in grey-market vials).
7. Aib² mechanism. v1 said "blocks DKP." v2 softens to "disfavors DKP via backbone φ/ψ restriction" — more mechanistically accurate.
8. Retatrutide linker chemistry. v1 said "γGlu-OEG-OEG" by analogy to sema. v2 says "similar to but not identical to" because the cryo-EM paper's linker description was not independently re-verified to match semaglutide's exactly.
9. Robinson Asn-Gly 24h figure. v1 cited it tied directly to PNAS 2001. v2 acknowledges the specific 24h number comes from the broader Robinson body of work, not that paper specifically; the 1–500-day range and Asn-Pro 500d are from PNAS 2001 directly.

Claims that survived fact-check intact

• Ozempic 56-day in-use, Mounjaro/Zepbound 21-day RT, KwikPen 30-day
• Robinson & Robinson 1–500 day deamidation range, Asn-Pro ~500 days
• Semaglutide pI 5.4, optimum pH ≥ 7 (Malgave 2025)
• Semaglutide CMC ~0.06 wt% (Biomacromolecules 2025)
• Retatrutide lipidation at Lys17 (Li/Sun 2024)
• Plasma half-lives: sema ~7d, tirz ~5d, reta ~6d
• Q10 ≈ 2 math for the temperature-rate table
• "Don't freeze reconstituted" recommendation (mechanism is sound)
• "Visual clarity doesn't prove potency" caveat
• Bottom-line storage recommendations

Retatrutide Stability After Reconstitution — Research Notes

Compound: Retatrutide (LY3437943), triple GIP/GLP-1/glucagon agonist, Eli Lilly
Regulatory status: Investigational — NOT approved by any agency as of May 2026
Phase: Phase 3 (TRIUMPH program, NCT05882045 etc.)

Confidence Tier Legend

• C1 = Primary data (peer-reviewed, manufacturer label, regulatory document)
• C2 = Credible secondary (review article, professional pharmacy guidance)
• C3 = Inferred by analogy from similar lipidated GLP-1 analogues (reasoning shown)
• C4 = Anecdotal / grey-market forum / vendor claim
• C5 = Unknown / not found

1. Direct Published Retatrutide Stability Data

Claim: No peer-reviewed quantitative stability data (degradation %/time at defined T, pH) for retatrutide has been published as of May 2026.
Confidence: C1 (negative finding) — extensive search of PubMed, Google Patents, Google Scholar, and clinicaltrials.gov yielded no primary stability study.
Source: PubMed retatrutide queries return only structural (cryo-EM) and clinical (NEJM/Lancet/Nat Med) papers; Eli Lilly has not published formulation or accelerated-stability data.
Notes: This is consistent with industry practice — Lilly's stability data is protected as part of the IMPD and will only appear in EMA/FDA assessment reports after first approval. The MHRA Bolt Pharmacy clinical-trial guidance explicitly states: "The beyond-use date for reconstituted retatrutide must be determined solely by the sponsor's validated stability data in the IMPD; generic timeframes from other peptides must not be applied." [https://www.boltpharmacy.co.uk/guide/how-to-store-reconstituted-retatrutide]

Claim: The cryo-EM structural paper (Sun et al. 2024) describes retatrutide as "acylated with various fatty diacid moieties via a linker connected to the lysine residues" at position 17 of the peptide.
Confidence: C1
Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC11255275/
Notes: This confirms retatrutide shares the albumin-binding lipidation strategy of semaglutide (C18 diacid at Lys26) and tirzepatide (C20 diacid at Lys20). No formulation data in this paper.

Claim: Retatrutide synthesis patent CN117903284A discloses solid-phase synthesis methodology but no stability, buffer, pH, or formulation parameters.
Confidence: C1
Source: https://patents.google.com/patent/CN117903284A/en
Notes: Likely a Chinese third-party synthesis patent; Lilly's own formulation patent has not been clearly located. The clinical-trial documents (NCT04143802, NCT04881760) do not disclose IMP handling details publicly.

2. Vendor / Compounding Pharmacy Claims for Retatrutide (Unverified)

Vendor claims cluster into a 2–8 week refrigerated window with wide variance:

Claim: Vendor consensus is 28–30 days refrigerated as the conservative window, with optimistic vendors extending to 6–8 weeks.
Confidence: C4 (anecdotal/marketing — no source cites primary data)
Source: https://alphacarbonlabs.com/blog/protocol-design-stability-data-and-storage-requirements-for-retatrutide-in-long-term-studies ; https://www.realpeptides.co/how-long-does-reconstituted-retatrutide-last/ ; https://www.seekpeptides.com/blog/articles/how-long-does-retatrutide-last ; https://glp3planner.com/resources/retatrutide-storage-stability ; https://palmettopeptides.com/blogs/news/07-how-to-store-retatrutide-research-peptide
Notes: None of these vendors cite peer-reviewed studies. The Alpha Carbon Labs "<1% / 1–3% / aggregation" timeline is suspiciously precise for a compound with no published data — likely extrapolated from semaglutide/tirzepatide or fabricated. Treat all vendor numbers as marketing.

3. Reasoning by Analogy: Semaglutide and Tirzepatide Stability

Retatrutide shares with semaglutide (and tirzepatide) a 39-aa GLP-1-family backbone acylated with a fatty diacid via a γGlu-OEG-OEG linker at a lysine. The degradation chemistry should be qualitatively similar; quantitative differences depend on sequence and lipid length.

Semaglutide solution stability (C1 primary data)

Claim: Semaglutide's most unstable pH window is 4.5–5.5 (at its isoelectric point pH 5.4), and the manufacturer-recommended finished-product pH is >7.0.
Confidence: C1
Source: Malgave et al. 2025, J Peptide Sci, https://onlinelibrary.wiley.com/doi/10.1002/psc.70039 ; abstract at https://pubmed.ncbi.nlm.nih.gov/40635175/
Notes: Tested at 25/40/55/80 °C; semaglutide was stable for 3 h at 80 °C in optimized buffer, suggesting strong intrinsic thermostability.

Claim: Semaglutide undergoes oxidation, deamidation (Asn → Asp/iso-Asp via succinimide), and hydrolysis in aqueous solution; six characteristic impurities form across all storage conditions.
Confidence: C1
Source: https://pubmed.ncbi.nlm.nih.gov/40490042/ ; https://www.daicelpharmastandards.com/blog/degradation-pathways-and-impurity-formation-in-glp-1-therapeutics/
Notes: Deamidation dominates at neutral-to-basic pH; direct hydrolysis dominates under acidic conditions. Methionine and tryptophan oxidation are the leading oxidative pathways.

Claim: Semaglutide forms low-MW oligomers (dimers/trimers) and spherical micelles in aqueous solution over 40–79 days at 4 °C, with a critical aggregation concentration of ~0.06 wt% (~0.6 mg/mL). Aged 1 wt% solution drifts from pH 5.5 → 7 over 40 days.
Confidence: C1
Source: Frka-Petesic et al. 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12152837/
Notes: Reconstituted research-grade retatrutide is typically used at 2–10 mg/mL — well above the CAC, so micelle/oligomer formation is expected. This is "off-pathway to fibrillation" for native GLP-1 but may differ for retatrutide.

Claim: Ozempic multi-dose pen label: in-use stability is 56 days at up to 30 °C after first puncture. Wegovy single-dose pen: 28 days at up to 30 °C if cap intact.
Confidence: C1 (regulatory label)
Source: Novo Nordisk prescribing info, https://www.novonordiskmedical.com/product-information/storage-and-stability/glp-1-ras.html
Notes: This is the strongest real-world anchor. Lilly's commercial semaglutide-class formulation tolerates 56 days at room temp post-puncture — but this uses optimized buffer, preservatives, and sealed pen architecture, not BAC-water reconstitution of bulk powder.

Tirzepatide solution stability

Claim: Lilly's tirzepatide patent (WO2024006662A1) defines "shelf-life stability" at ~5 °C and "in-use stability" at ~25 °C as degradation within regulatory limits; specifies forced-degradation under acid, base, peroxide, and thermal stress.
Confidence: C1
Source: https://patents.google.com/patent/WO2024006662A1/en
Notes: No exact numbers extractable, but confirms Lilly designs lipidated triple/dual agonists for ≥28-day in-use stability at 25 °C in optimized formulation.

GLP-1 lipidation effects on aggregation

Claim: Lipidation of GLP-1 analogues reduces aqueous solubility within a narrow pH window, promotes α-helical structure, and accelerates oligomer formation. Position of lipidation determines morphology — N-terminal lipidation produces β-sheet fibrillar aggregates; semaglutide/liraglutide-style mid-chain Lys20 lipidation forms more benign micelles.
Confidence: C1
Source: https://pubmed.ncbi.nlm.nih.gov/39841169/ (Bioconjugate Chem 2025); https://pmc.ncbi.nlm.nih.gov/articles/PMC11926786/
Notes: Retatrutide's lipidation at position 17 is structurally similar to semaglutide's at Lys26 — should give micelle-type, not fibrillar, aggregation.

4. Inferred Retatrutide Stability (C3 — Reasoned by Analogy)

Claim: Reconstituted retatrutide in BAC water at 2–8 °C is likely chemically stable (<5% degradation) for 28–56 days, comparable to the Ozempic in-use window.
Confidence: C3
Reasoning: (a) Same backbone family; (b) similar lipidation chemistry → similar deamidation/oxidation kinetics; (c) commercial semaglutide has 56-day in-use stability at up to 30 °C in optimized formulation; grey-market BAC-water reconstitution is suboptimal buffer (BAC water is non-buffered, pH ~5–6 with benzyl alcohol) so expect shorter usable life than the commercial pen.
Source: Synthesis of the above primary data.
Notes: "Likely" is doing work here. Without access to retatrutide's pH optimum, this could be off by 2x in either direction.

Claim: Retatrutide degradation roughly doubles for every +10 °C rise (Arrhenius rule of thumb).
Confidence: C3
Reasoning: General peptide pharmaceutics principle; semaglutide stability studies span 25/40/55/80 °C and show this trend qualitatively.
Source: Standard pharmaceutical kinetics; https://www.realpeptides.co/how-long-can-tirzepatide-stay-out-of-the-fridge/
Notes: Implies: if 28 days at 4 °C, expect ~14 days at 14 °C, ~7 days at 24 °C, ~3.5 days at 34 °C — back-of-envelope only.

Claim: Retatrutide likely degrades faster in BAC water (pH ~5–6, near isoelectric for GLP-1 analogues) than in pH 7.4 phosphate buffer.
Confidence: C3
Reasoning: Semaglutide is least stable at pH 4.5–5.5; Lilly recommends pH >7 in finished product. BAC water provides no pH control.
Source: Malgave 2025; standard formulation science.
Notes: Adding a small amount of sterile sodium phosphate buffer would theoretically extend life — but no grey-market protocols do this and there are sterility concerns.

Claim: Freeze-thaw is more damaging to retatrutide than to non-lipidated peptides because ice crystal formation disrupts micelle organisation and increases solute concentration in unfrozen channels — accelerating aggregation/fibrillation.
Confidence: C3
Reasoning: Lipidated peptides form micelles above CAC; freezing concentrates solute >100-fold in unfrozen liquid pockets, well above CAC, promoting irreversible aggregation. Multiple sources (vendor and primary) warn against freezing reconstituted GLP-1 analogues.
Source: Standard biopharmaceutical principle; vendor consensus.

Claim: Retatrutide may be slightly MORE prone to instability than semaglutide because (a) it is a 39-aa peptide vs semaglutide's 31 aa — more degradation sites; (b) it must satisfy three receptor binding interfaces, leaving less sequence flexibility for stabilizing substitutions; (c) grey-market synthesis purity is typically lower (98–99% vs. Lilly's >99.5%), and initial impurities catalyze further degradation.
Confidence: C3
Reasoning: Structural and biochemical inference. Higher initial impurity = more catalytic surfaces and more aggregation seeds.
Source: https://happypeptides.com/blogs/peptide-research/verifying-retatrutide-quality-a-researchers-guide-to-purity-hplc-and-coas
Notes: This argues for a CONSERVATIVE (shorter) shelf-life when using grey-market product — closer to 21–28 days than 56 days.

5. Half-Life Comparison (Indirect Stability Indicator)

Claim: Retatrutide's plasma half-life is intermediate, suggesting its albumin-binding moiety is similarly effective; this does NOT directly translate to solution shelf-life (in-vivo protection by albumin is different chemistry than aqueous storage).
Confidence: C3
Notes: Often misquoted as evidence of solution stability. Plasma t½ reflects clearance, not chemical degradation kinetics.

6. Grey-Market / Community Practice

Direct reddit fetches were blocked, but synthesised community guidance from multiple peptide-community blogs:

Claim: Biohacker consensus practice is 4–6 weeks refrigerated; some report 8 weeks without subjective efficacy loss.
Confidence: C4
Source: https://www.realpeptides.co/retatrutide-reddit-reviews-community/ ; https://stageresearch.co/research-storage-how-long-does-retatrutide-last/
Notes: "Subjective efficacy" is unreliable — denatured peptide is visually identical to active.

Claim: Reported failure mode = "received warm vial in summer shipping" → no clinical effect at therapeutic doses (≥6 mg). Forum advice when no response at 4+ weeks: suspect potency loss.
Confidence: C4
Source: https://www.realpeptides.co/retatrutide-reddit-reviews-community/
Notes: Plausible but no quantitative attribution.

Claim: Aliquoting into single-use vials before freezing (-20 °C) is the standard biohacker workaround for extending shelf-life beyond 4 weeks.
Confidence: C4
Source: Multiple vendor guides.
Notes: Conflicts with vendor warnings against freezing. Single freeze (no thaw cycles) is probably acceptable but unproven for retatrutide specifically.

7. Summary Table — Best Inference

8. Honest Knowledge Gaps

• No published forced-degradation study specific to retatrutide.
• No HPLC purity-vs-time data at standardized conditions in any public document.
• Lilly's formulation patent (if filed) was not located — pH optimum, buffer, preservative system for retatrutide unknown.
• No comparison data between grey-market lyo (typically pH unbuffered, recon in BAC water) vs. Lilly's investigational formulation.
• No human PK study of retatrutide dosed from a vial stored >28 days vs. fresh.
• Reddit discussion of retatrutide stability could not be fetched directly; synthesised second-hand only.

Bottom Line

The honest answer to "how long does reconstituted retatrutide last?" is: probably 4–6 weeks at 2–8 °C, with chemistry analogous to semaglutide's 56-day pen label, but this rests on analogy, not direct data. Use within 28 days is conservative and defensible. Room-temperature exposure accelerates degradation roughly Arrhenius-style (~2× per 10 °C). Freeze-thaw cycles are particularly damaging to lipidated GLP-1 analogues. BAC-water reconstitution is suboptimal vs. Lilly's likely pH ~7+ buffered formulation, so grey-market shelf-life should be discounted relative to commercial in-use windows. The single biggest unknown is retatrutide-specific pH stability profile.

Semaglutide Stability After Reconstitution — Research Notes

Compiled 2026-05-23 for the peptide compendium. Confidence tags: C1 primary (FDA label, peer-reviewed); C2 credible secondary (clinic/pharma blog citing labels); C3 inferred from analogous data; C4 anecdotal/community; C5 unknown/conflicting.

1. Pharmaceutical Product Labels (highest-quality data)

1.1 Ozempic pen (Novo Nordisk)

Claim: Unopened Ozempic pens are stored refrigerated at 36–46 °F (2–8 °C) until expiration. After first use, the pen is good for 56 days stored either refrigerated (2–8 °C) or at room temperature 59–86 °F (15–30 °C). Must not be frozen; discard if frozen.
Confidence: C1
Source: Novo Nordisk Medical, "GLP-1 RAs Storage & Stability" https://www.novonordiskmedical.com/product-information/storage-and-stability/glp-1-ras.html ; FDA label PDF https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209637s020s021lbl.pdf
Quote (Novo Nordisk): "Ozempic® can be used as long as the product has not been exposed to temperatures below 36 °F or above 86 °F."
Notes: Important: the 56-day clock starts at first room-temperature excursion or first use, whichever is sooner — i.e., once it's been warm, it's a 56-day product regardless of going back into the fridge.

1.2 Wegovy pen (Novo Nordisk)

Claim: Unopened Wegovy refrigerated until expiration. Once exposed to room temperature 46–86 °F (8–30 °C), discard within 28 days. Do not freeze.
Confidence: C1
Source: https://www.novonordiskmedical.com/product-information/storage-and-stability/glp-1-ras.html ; https://www.healthline.com/health/drugs/wegovy-and-refrigeration
Notes: Same molecule and (nearly) same formulation as Ozempic, but Wegovy carries a 28-day RT shelf life vs Ozempic's 56-day. This is a regulatory/packaging-driven difference (single-use vs multi-use, dose volume), not a pure chemistry difference. Interesting datapoint: Novo's own data show semaglutide solution is good at 30 °C for at least 28 days.

1.3 Rybelsus oral tablets

Claim: Tablets stored at 68–77 °F (20–25 °C) with excursions allowed to 59–86 °F (15–30 °C). Different chemistry — semaglutide co-formulated with SNAC (sodium N-[8-(2-hydroxybenzoyl)amino] caprylate) absorption enhancer. Stored DRY at room temperature; not refrigerated.
Confidence: C1
Source: https://www.novonordiskmedical.com/product-information/storage-and-stability/glp-1-ras.html ; EMA Rybelsus assessment report https://www.ema.europa.eu/en/documents/assessment-report/rybelsus-epar-public-assessment-report_en.pdf
Notes: EMA stability data: tested at 25 °C/60% RH for 30 months, 30 °C/75% RH for 30 months, 40 °C/75% RH for 6 months. Solid-state semaglutide is very stable — the lyophilized peptide on its own is essentially shelf-stable for years if dry and cool.

1.4 Compounded semaglutide (US compounding pharmacies)

Claim: Compounded reconstituted semaglutide typically carries a 28-day beyond-use date (BUD) when refrigerated, per USP <797> rules for multi-dose sterile preparations preserved with bacteriostatic water. Some pharmacies extend to 30–60 days based on internal stability testing; a few cite up to 120 days.
Confidence: C2
Source: TrimRX https://trimrx.com/blog/compounded-semaglutide-dosage-chart-reconstitution/ ; Fella Health https://www.fellahealth.com/guide/how-to-store-semaglutide ; SeekPeptides https://www.seekpeptides.com/blog/articles/semaglutide-shelf-life
Notes: The 28-day USP <797> default is driven by sterility assurance (max bacteriostatic-water in-use date), not chemical stability. Most compounders adopt 28 days conservatively. The lyophilized API itself is stable far longer; the limitation is microbiological once water is added.

2. Published Stability/Degradation Studies

2.1 Optimum pH and pH-dependent degradation

Claim: Semaglutide is most stable at neutral-to-slightly-alkaline pH (≥ 7.0); commercial formulations target pH 7.4. Maximum degradation occurs at pH 4.5–5.5, near the isoelectric point (pI ≈ 5.4).
Confidence: C1
Source: Malgave et al. 2025, J Peptide Science, "Influence of Buffering Capacity, pH, and Temperature on the Stability of Semaglutide" https://pubmed.ncbi.nlm.nih.gov/40635175/ ; Malgave et al. 2025, Eur J Pharm Biopharm, https://pubmed.ncbi.nlm.nih.gov/40490042/
Quote: "SEMA was relatively stable at pH 1.2 at 25 °C and 40 °C for a day. A higher extent of degradation was observed between the pH of 4.5–5.5... the finished product pH should be > 7.0."
Notes: Ozempic is formulated at pH ~7.4 in disodium phosphate buffer with phenol preservative — chosen for chemical stability. Bacteriostatic water (0.9% benzyl alcohol) is essentially neutral (~5.7-7), but with no buffering capacity; reconstituted semaglutide solutions sit at the peptide's own pH (~7 at aged 1 wt%).

2.2 Aqueous aggregation kinetics (Biomacromolecules 2025)

Claim: Semaglutide in aqueous solution slowly aggregates into oligomeric micelles (radius ~2.3–2.5 nm, association number ~30) over ~40 days at 4 °C. Once formed, micelles are stable (no further morphological change at 79 days). Below the critical micelle concentration of 0.06 wt%, only dimers/trimers form.
Confidence: C1
Source: Biomacromolecules 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12152837/
Notes: At typical reconstituted compounding concentrations (2–5 mg/mL = 0.2–0.5 wt%) we are well above CMC, so micelle formation occurs over weeks of refrigerated storage. Fresh semaglutide had ~80% TEER reduction (epithelial permeability marker) at 30 min vs aged samples having less — i.e., aggregation does reduce bioactivity in vitro, though aggregated forms still retain some activity (the micelles are reversible-ish on dilution).

2.3 Forced degradation (HPLC stability-indicating studies)

Claim: Acid stress yields ~14 impurities; base ~13; oxidation (H₂O₂) ~18; thermal up to ~35. Oxidative degradation produces methionine sulfoxide (Met oxidation at Met14 of the peptide). Alkali yields deamidation products (Asn/Gln → Asp/Glu).
Confidence: C1
Source: Phenomenex tech note https://www.phenomenex.com/-/jssmedia/phxjss/data/media/documents/1699823599-tn0725.pdf ; BMC Chemistry 2025 https://link.springer.com/article/10.1186/s13065-025-01716-7 ; MDPI review https://www.mdpi.com/2227-9059/11/8/2127
Notes: Main pathways: (1) Met oxidation, (2) Asn/Gln deamidation, (3) backbone hydrolysis at Ser-Tyr / Tyr-Leu / Glu-Phe / Trp-Leu sites, (4) physical aggregation/fibril. Fatty-acid C18 di-acid side chain is relatively hydrolysis-resistant.

2.4 Arrhenius / Q10 — temperature dependence

Claim: No published Arrhenius activation energy (Ea) for semaglutide aqueous degradation found in open literature.
Confidence: C5 (unsourced)
Notes: This is a real gap. The Malgave preformulation study tested 5/25/40/60/80 °C but only published % degradation per condition without fitting Arrhenius. For peptide drugs generally, Ea ≈ 80–120 kJ/mol → Q10 (rate increase per 10 °C) ≈ 2.5–4×. Inferred: moving semaglutide from 4 °C to 25 °C should accelerate chemical degradation by roughly 8–15×; from 4 °C to 37 °C by roughly 40–80×. Treat as C3 estimate, not measured.

2.5 Thermal degradation specifics

Claim: Semaglutide "remained stable for 3 h at 80 °C." Solid lyophilized semaglutide tolerates 25 °C/60% RH for 30 months and 40 °C/75% RH for 6 months (Rybelsus tablet data).
Confidence: C1
Source: Malgave 2025 https://pubmed.ncbi.nlm.nih.gov/40635175/ ; EMA Rybelsus assessment https://www.ema.europa.eu/en/documents/assessment-report/rybelsus-epar-public-assessment-report_en.pdf

3. Reconstituted/Aqueous Solution Specifics

3.1 Bacteriostatic water (0.9% benzyl alcohol)

Claim: Benzyl alcohol does not hydrolyze peptide bonds at 2–8 °C. It serves as antimicrobial only; chemical stability of semaglutide in BAC is comparable to plain sterile water, but BAC permits multi-dose use (~28 days before microbial concern dominates).
Confidence: C2
Source: https://www.seekpeptides.com/blog/articles/bacteriostatic-water-for-peptides ; https://www.projectbiohacking.com/bacteriostatic-water-for-peptides
Notes: BAC's own shelf life after first puncture is 28 days per USP, which sets the practical ceiling for multi-dose semaglutide regardless of the peptide's intrinsic chemical stability.

3.2 Adsorption to vial surfaces

Claim: Semaglutide adsorbs to plastic and glass surfaces at low concentrations (sub-µg/mL), relevant to bioanalytical handling but NOT typically a problem at biohacker reconstitution concentrations (mg/mL range).
Confidence: C2
Source: Waters bioanalytical application note https://www.waters.com/nextgen/us/en/library/application-notes/2023/spe-lc-ms-bioanalytical-quantification-of-the-biotherapeutic-peptide-semaglutide-from-plasma.html
Notes: Surface-mediated emulsification described in PNAS https://www.pnas.org/doi/10.1073/pnas.2305770121 (concentration-dependent). At 2–5 mg/mL reconstituted concentrations, surface losses are <1% even over weeks — not the limiting factor.

3.3 Freezing

Claim: Freezing is officially contraindicated for all semaglutide products. Ice crystal formation can disrupt peptide structure and trigger aggregation/fibrillation on thaw.
Confidence: C1 (label) / C2 (mechanism)
Source: Ozempic/Wegovy labels; https://www.fellahealth.com/guide/can-you-freeze-semaglutide
Notes: Some peptides freeze fine if cryoprotectants are present (e.g., sucrose). Ozempic/Wegovy formulations lack cryoprotectants — so the contraindication holds for commercial product. For lyophilized API, freezing the dry powder is fine and even extends shelf life; the contraindication is for aqueous solution.

4. Community/Grey-Market Reports

4.1 Common practice in biohacker community

Claim: Common reported practice: reconstitute semaglutide in BAC, refrigerate, use within 4–8 weeks. Many users self-report using vials for 6–12 weeks without subjective efficacy loss.
Confidence: C4
Source: SeekPeptides blog (citing community discourse) https://www.seekpeptides.com/blog/articles/semaglutide-shelf-life ; Hacker News thread https://news.ycombinator.com/item?id=41928524
Notes: Could not directly fetch r/Semaglutide or r/peptides (WebFetch blocked); secondary summaries consistently report "28-day rule is conservative; 56 days commonly used; some users go 8–12 weeks." No systematic reports of solutions going visibly bad (yellow/cloudy) within a 2-month window for properly refrigerated product.

4.2 Color/visual changes

Claim: Clear solution turning yellowish or cloudy indicates degradation/aggregation; should be discarded.
Confidence: C2
Source: https://www.seekpeptides.com/blog/articles/why-is-my-semaglutide-red ; https://casadesante.com/blogs/gut-health/identifying-semaglutide-what-color-is-it-and-what-it-indicates
Notes: Visual changes are a LATE-stage indicator. By the time color/cloudiness appears, substantial degradation has already occurred. Absence of visual change does NOT prove potency.

5. Numbers to Extract — Temperature/Time Summary

Quantitative degradation rate: Not directly published. Inferring from Ozempic's 56-day RT shelf life implying typically <5% degradation over 56 days at ≤30 °C → roughly <0.1% per day at room temp, < 0.05% per day refrigerated. Aggregation kinetics (~40 days to micelle formation at 4 °C) is the more practically-limiting process for very long-term storage.

6. Contradictions / Open Questions

1. Wegovy 28 d vs Ozempic 56 d at room temp — same molecule. Likely due to single-dose vs multi-dose packaging design, not chemistry. Implication: chemistry probably supports ≥56 days at RT for any semaglutide in well-buffered formulation.
2. Compounded 28-day BUD vs Ozempic 56-day in-use — the compounded limit is microbiological (USP <797> default for BAC-preserved multi-dose vials), not chemical. Ozempic's longer in-use limit is supported by full ICH stability dossier with antimicrobial efficacy data.
3. No published Arrhenius Ea for semaglutide aqueous degradation — major data gap. The Malgave 2025 papers collected the data but did not fit it.
4. No published % degradation/week numbers at common temperatures — only "stable within label" categorical claims; the regulatory binary obscures the rate.
5. Aggregation vs chemical degradation — micelle formation in 40 days at 4 °C (Biomacromolecules 2025) is the LIKELY rate-limiter for long refrigerated storage. The aggregated form retains some GLP-1 receptor activity but reduced epithelial permeability.

7. Bottom-line for the compendium

• Refrigerated (2–8 °C) reconstituted semaglutide in BAC: chemistry comfortably supports 6–8 weeks. 28-day BUD on compounded product is microbiological, not chemical. Conservative biohacker default: 4 weeks; aggressive but plausible: 8 weeks.
• Room temperature (15–30 °C): Ozempic's own label allows 56 days. Equivalent stability at room temperature and refrigerator is unusual but supported for this formulation — implies activation energy is relatively modest below 30 °C, OR that the rate-limiting process below 30 °C is non-thermal (e.g., aggregation triggered by interface effects).
• Above 30 °C / body temp: Sharp drop in stability. No formal data <86 °F to 98 °F band; treat anything ≥37 °C exposure for >24 h as suspect.
• Freeze: Don't.
• Key gotcha: Visual clarity does NOT prove potency. Slow chemical degradation (Met oxidation, Asn deamidation) is invisible.

Unsourced / could not find

• Exact % degradation per week at refrigerator vs room temp from peer-reviewed paper (Malgave studies have the raw data but not in extracted form I could access — full text was paywalled at Wiley/ScienceDirect; PubMed abstracts only).
• Activation energy / Ea for semaglutide.
• Direct Reddit thread quotes (Reddit fetch blocked from this environment; relied on secondary summaries).

Tirzepatide Stability After Reconstitution — Research Notes

Compiled: 2026-05-23
Purpose: Reference data for retatrutide stability inferences (both are Lilly GLP-1/GIP agonists with C20 fatty diacid pendant).
Confidence legend: C1 primary (FDA label, peer-reviewed) / C2 credible secondary / C3 inferred / C4 anecdotal/Reddit/grey-market / C5 unknown.

1. FDA / Regulatory Labels (Manufactured Product)

Note: Mounjaro and Zepbound are pre-filled aqueous solutions (not lyophilized), so their in-use stability is the closest official analogue for "reconstituted" tirzepatide in a buffered aqueous solution.

Claim: Unopened Mounjaro/Zepbound pens and single-dose vials are stored 2–8 °C (36–46 °F) until labeled expiry.
Confidence: C1
Source: Eli Lilly Mounjaro IFU; FDA Zepbound label
Notes: Original carton, protect from light.

Claim: Mounjaro/Zepbound (single-dose pen or single-dose vial) may be stored at ≤30 °C (86 °F) for "up to a total of 21 days" and must be discarded after 21 days at room temp.
Confidence: C1
Source: Lilly IFU and FDA label (above); confirmed by Medical News Today, GoodRx
Direct quote (Lilly IFU): "The Pen may be stored at room temperature up to 86 °F (30 °C) for up to a total of 21 days, and should be discarded after a total of 21 days at room temperature."
Notes: Once out of refrigerator, the FDA label says do not return to fridge. The 21-day "room temp" window is the closest hard regulatory number we have for aqueous tirzepatide stability at ~22–30 °C.

Claim: The multi-dose Mounjaro KwikPen (UK formulation; same molecule, different device) has a 30-day in-use period at ≤30 °C, and refrigerator↔room-temp cycling is permitted during that 30 days.
Confidence: C1
Source: Lilly Medical UK FAQ (via secondary summary; Lilly UK material 403'd direct fetch)
Notes: This is a useful upper-bound data point — Lilly themselves have validated aqueous tirzepatide for 30 days at ≤30 °C with thermal cycling in the KwikPen multi-dose formulation. Likely indicates the formulation is robust enough that ~30 days at ambient is the practical limit Lilly is willing to label.

Claim: Freezing destroys tirzepatide; any frozen pen/vial must be discarded.
Confidence: C1
Source: Lilly IFU; FDA label
Direct quote: "Do not freeze the Pen; if the Pen has been frozen, throw the Pen away and use a new Pen."
Notes: This applies to the aqueous product. Lyophilized powder behaves differently (see §3).

Claim: Zepbound single-dose vial follows the same storage rules as the pen.
Confidence: C1
Source: Zepbound vial IFU; FDA label
Notes: 2–8 °C until expiry; ≤30 °C for ≤21 days; no freeze; protect from light. Vials, like pens, are pre-filled aqueous (not lyophilized).

2. Published Peer-Reviewed Stability / Forced Degradation

Claim: Stability-indicating RP-HPLC method has been published (BMC Chemistry 2025) covering acid, base, oxidative, thermal, and photolytic forced degradation of both semaglutide and tirzepatide.
Confidence: C1
Source: BMC Chemistry 2025; PMC12918740; Springer DOI

Claim: Forced degradation extents reported (tirzepatide standard solution):
- Acid (0.1 M HCl, 25 °C, 10 min): 16.90 % degraded
- Base (0.1 M NaOH, 25 °C, 20 min): 18.97 % degraded (vs SEM 13.00 % — tirzepatide more base-labile)
- Oxidative (10 % H₂O₂, 25 °C, 60 min): 15.91 % degraded
- Wet heat (reflux 60 °C, 90 min): 17.90 % degraded
- Photolytic (direct sunlight, 25 °C, 24 h): 11.84 % degraded
Confidence: C1
Source: PMC12918740 (above)
Notes: These are stressed conditions intended to force degradation for analytical method validation, NOT real-world rates. But they tell us: (a) tirzepatide is more base-sensitive than semaglutide; (b) it's vulnerable to all major pathways — oxidation, hydrolysis, photolysis, heat; (c) at neutral pH, 25 °C, real-time degradation is much slower.

Claim: Tirzepatide is "most prone to oxidation at pH 5, even when stored at 5 °C."
Confidence: C2 (cited by Phenomenex technical literature based on published methods)
Source: Phenomenex HPLC tech note
Notes: Suggests acidic pH excursions are particularly damaging even at fridge temp.

Claim: Tirzepatide aqueous formulations show acceptable stability at pH 6.5–7.5 for at least 6 months.
Confidence: C1 (patent disclosure with stability data)
Source: WO2024006662A1 (Lilly tirzepatide compositions patent); WO2025141472A1 (stable tirzepatide compositions)
Notes: Patent claims stability at 2–8 °C and 25 °C/60 %RH and 30 °C/65 %RH for "about 6 months… about 12 months… up to about 36 months." Buffer = 5 mM sodium phosphate, 140 mM NaCl, pH 7. Specific % impurity tables exist in Tables 10–11 but are image-only in the patent and not transcribable from the fetch.

Claim: The Mounjaro/Zepbound commercial formulation uses ~pH 6.5–7.5 phosphate-buffered saline, with no antimicrobial preservative in single-dose presentations.
Confidence: C2 (from patent and label inference)
Source: WO2024006662A1 (above); WO2024086601A2 (preserved GIP/GLP compositions)
Notes: Multi-dose presentations (e.g., KwikPen) may include preservative — likely a paraben or phenol class; benzyl alcohol typically only via bacteriostatic-water reconstitution.

Claim: Lipidation (the C20 fatty diacid tail) reduces aqueous solubility and promotes self-assembly into oligomeric micelles, with a minor fibril population observable at higher concentration. This is documented for semaglutide; tirzepatide presumably behaves similarly.
Confidence: C2 (analogous data; tirzepatide-specific paper not located)
Source: Biomacromolecules 2025, semaglutide aggregation; Bioconjugate Chem 2024, lipidation of GLP-1
Notes: Once formed, micelles are stable and do not progress; fibrillation is the worry. Solubility is pH-dependent.

3. Lyophilized vs Aqueous (relevant for compounded / "research" product)

Claim: Lyophilized tirzepatide stored at −20 °C retains >98 % potency for >24 months; at −80 °C, >3 years.
Confidence: C2 (vendor/technical-note level, not peer-reviewed)
Source: Palmetto Peptides lab protocol; SeekPeptides lyophilized guide
Notes: Frost-free freezers (auto-defrost cycle) are warned against. No peer-reviewed paper for these exact numbers, but consistent with general lyophilized-peptide best practice.

Claim: Lyophilized tirzepatide at 2–8 °C is stable for 12–24 months; at room temperature, "several days to a week" is tolerated without significant degradation.
Confidence: C2
Source: Palmetto Peptides, SeekPeptides (above); Ro tirzepatide guide

Claim: Once reconstituted with bacteriostatic water (0.9 % benzyl alcohol) and stored at 2–8 °C, tirzepatide is conventionally treated as stable for 28 days (preservative-driven BUD), with some pharmacies extending to 30, 60, or even 90 days.
Confidence: C2 for the 28-day figure (matches USP <797> conventions for multi-dose preserved vials); C3 for 60–90 day extensions (depends on stability data on file).
Source: SeekPeptides BUD guide; RealPeptides fridge guide; Blue Medi Spa
Notes: The 28-day BUD is driven primarily by preservative effectiveness of benzyl alcohol, not by tirzepatide chemical degradation per se. Chemical degradation at 4 °C is slower than 28 days; the limit is microbiological.

Claim: Reconstituted in sterile (non-bacteriostatic) water, the conservative use window collapses to 24 hours at 2–8 °C — purely a sterility concern.
Confidence: C2 (USP <797> default; widely repeated)
Source: SeekPeptides, Palmetto Peptides (above)

Claim: "Measurable degradation begins within 4–6 weeks" of refrigerated reconstituted solution at 2–8 °C.
Confidence: C3 (vendor claim, no primary citation found)
Source: SeekPeptides shelf-life
Notes: Roughly consistent with the Lilly KwikPen 30-day room-temp label (which would translate to substantially longer at 4 °C via Q10 ~2–3).

Claim: Reconstituted tirzepatide must NOT be frozen — ice-crystal-mediated mechanical disruption causes irreversible aggregation/fibrillation. Multiple freeze-thaw cycles accelerate aggregation.
Confidence: C1 (Lilly label) + C2 (general lipidated-peptide principle)
Source: Lilly IFU; Bioconjugate Chem paper above
Notes: This is the single most reliable "do not" rule across all sources.

4. Temperature-Specific Synthesis (best inference from above sources)

5. Numerical Degradation Rates / Q10 / Arrhenius

Claim: Tirzepatide-specific Arrhenius parameters or activation energy values are not publicly available in indexed literature.
Confidence: C5
Notes: Lilly patent stability tables (WO2025141472A1, Tables 10–11) contain real-time and accelerated data but are image-only in the disclosure. Indirect inference: if Lilly allows 21 days at 30 °C and labels 24+ months at 5 °C, the implied Q10 is in the ~2.5–3 range typical for peptide hydrolysis — consistent with general peptide-degradation kinetics. Cannot be cited as a measured number.

Claim: Quantitative "% degraded per week" at 2–8 °C, 22 °C, 37 °C for reconstituted tirzepatide could NOT be located in peer-reviewed literature.
Confidence: C5
Notes: This is the most important gap. The forced-degradation %s (§2) are at stressed conditions only and not extrapolatable cleanly.

6. Community / Grey-Market Evidence (C4 throughout)

Claim: Common Reddit/biohacker practice: keep reconstituted tirzepatide in fridge for 30 days (conservative) up to 60–90 days (aggressive); many users report no perceived efficacy loss out to 8–12 weeks.
Confidence: C4
Source: Aggregated from compounding-pharmacy blogs that mirror community discussion (SeekPeptides shelf-life, SeekPeptides BUD); direct Reddit threads were not retrievable by web search.
Notes: "Looks normal but lost 20–50 % potency" is a frequent warning. Self-reported efficacy is a noisy signal because GLP-1/GIP weight loss is slow and dose-titrated.

Claim: Many users keep their Mounjaro/Zepbound pens at room temperature throughout an injection cycle (~1 week per pen at higher doses) without subjective issue, within the 21-day label window.
Confidence: C4 → C2 (label-consistent, widely reported)
Source: Pillo; Drugs.com Q&A

7. Contradictions / Gaps Flagged

1. 28-day BUD vs. 6+ month patent stability. The 28-day rule for compounded reconstituted tirzepatide is preservative/sterility-driven, NOT chemical-stability-driven. Lilly's own patent data shows the aqueous formulation is chemically stable at 2–8 °C for 6+ months. The two numbers are not contradictory — they answer different questions (microbiology vs. potency).
2. "Several months in fridge" (vendor) vs. "21–30 days" (FDA label). Vendor claims for reconstituted compounded product (28–90 d in fridge) exceed the FDA label's room-temp window but are below the patent's chemical-stability data. Vendors appear to choose 28–60 d as a conservative compromise.
3. No 37 °C data. A critical gap given that insulin-pen-style accidental thermal excursions (car, pocket, body warmth during injection) are common. Best inference is "discard if hot to touch for hours."
4. Lyophilized tirzepatide is not a commercial dosage form. All FDA-labeled product is pre-filled liquid. "Lyophilized tirzepatide" data comes from research/grey-market vendors and lacks peer-reviewed validation.
5. Retatrutide-specific data was not searched here but the structural analogy is strong: both have the C20 fatty diacid at K20, both made by Lilly, both presumed to use similar phosphate-buffered ~pH 7 aqueous formulation. Retatrutide stability is reasonably inferred to be at least as good as tirzepatide under matched conditions.

8. Bottom-Line Take for Retatrutide Inference

• Refrigerator (2–8 °C), reconstituted with bacteriostatic water: safe usability window is ~28 days (sterility-bounded) with chemical potency likely intact for 6–8 weeks based on tirzepatide analogue patent and label data. (C1/C2)
• Room temperature (≤30 °C), aqueous: 21 days is the FDA-validated outer envelope for tirzepatide. Apply this directly. (C1)
• Freeze: Do not freeze reconstituted solution. Freezing lyophilized powder is fine and preserves it for years. (C1 for reconstituted; C2 for lyophilized)
• Above 30 °C / hot car / body-temp for hours: treat as failed; discard. (C2)
• Watch for cloudiness, particulates, color change — but absence of visual change does NOT prove potency. Subjective efficacy on a 1–2 week titration is not a reliable potency assay. (C2)

Peptide Degradation Chemistry in Aqueous Solution

Scope: Reference material on degradation pathways, temperature dependence, and sequence/formulation predictors of peptide stability. Compiled to frame the GLP-1 analogue stability discussion.

Confidence scale: C1 peer-reviewed primary; C2 peer-reviewed review; C3 textbook/inferred; C4 anecdotal/industry blog.

1. Major Degradation Pathways

1.1 Deamidation (Asn, Gln)

Claim: Asn deamidation in unstructured peptides shows sequence-determined half-lives of 1–500 days at pH 7.4 / 37 °C; Gln deamidation half-lives are 100–>5,000 days at the same conditions.
Confidence: C1.
Source: Robinson & Robinson, PNAS 2001 — https://pmc.ncbi.nlm.nih.gov/articles/PMC60067/
Notes: Range covers ~500-fold variation driven almost entirely by primary sequence.

Claim: Asn-Gly (NG) is the canonical "hot spot": half-life ~24 h at pH 7.4, 37 °C in flexible peptides. Asn-Ser, Asn-His, Asn-Asn, Asn-Ala are also fast. Asn-Pro is the slowest dipeptide context (~500 d).
Confidence: C1.
Source: Robinson & Robinson, PNAS 2001; Patel & Borchardt, Pharm Res 1990 — https://link.springer.com/content/pdf/10.1023/A:1015807303766.pdf
Notes: Mechanism is intramolecular nucleophilic attack of the i+1 backbone NH on the Asn side-chain carbonyl, forming a cyclic succinimide (aminosuccinyl) intermediate that hydrolyzes to a mixture of L-Asp and L-iso-Asp (~3:1 in favor of iso-Asp), plus D-isomers. Small/flexible i+1 residues (Gly, Ala, Ser) allow the geometry; bulky/Pro residues block it.

Claim: Deamidation rate is minimal near pH 4–5 and rises sharply at pH > 6; above pH 9 the cyclic-imide pathway dominates strongly. Phosphate buffer catalyzes deamidation ~2-fold over Tris at matched pH/ionic strength.
Confidence: C1.
Source: Patel & Borchardt 1990; Robinson 2001 (PMC60067 above).
Notes: Implication: phosphate-buffered formulations (common for peptides) can underperform vs. acetate or histidine on this axis.

Claim: Apparent activation energy for deamidation in a flexible model peptide: Ea ≈ 13.3 kcal/mol (≈ 56 kJ/mol) between 5 and 65 °C, following Arrhenius behavior.
Confidence: C1.
Source: Capasso et al., later confirmed in additives study — https://www.sciencedirect.com/science/article/abs/pii/S0022354916305147
Notes: Ea ~13 kcal/mol corresponds to Q10 ≈ 2.0–2.3 in the 4–40 °C range — the canonical "doubles per 10 °C" rule of thumb derives from values like this.

1.2 Oxidation (Met, Cys, Trp, Tyr, His)

Claim: Met → Met-sulfoxide is the most common oxidative liability; rate is set by trace ppm-level transition metals (Fe, Cu) plus dissolved O₂, not by Met content alone. Cu²⁺ is the most efficient catalyst with a computed activation barrier of 14.3 kcal/mol, vs. 19.6 (Zn²⁺) and 16.9 (Fe³⁺) kcal/mol.
Confidence: C1.
Source: Schöneich et al. (Pharm Res series VIII) — https://link.springer.com/article/10.1023/A:1016240115675 ; computational study — https://pubmed.ncbi.nlm.nih.gov/19037857/
Notes: Ascorbate is pro-oxidant for Met under metal-catalyzed conditions (counterintuitive for formulators).

Claim: Met oxidation rate maximizes at pH 6–7 and is markedly accelerated by His residues 1–2 positions away from Met (the His coordinates the metal and positions the oxidant).
Confidence: C1.
Source: Schöneich Pharm Res series (V and VIII) — https://link.springer.com/article/10.1023/A:1018960300769
Notes: Cys and Trp oxidation pathways are distinct; Trp → kynurenine/N-formyl-kynurenine is photolytically driven (UV-A/B) and explains why amber vials matter.

Claim: Free Cys (not in a disulfide) is the fastest-oxidizing residue under air; rate is high enough that EDTA chelation + N₂ headspace is standard practice for Cys-containing peptide formulations.
Confidence: C2.
Source: Manning, Patel & Borchardt, Pharm Res 6:903 (1989); Manning et al. update — https://link.springer.com/article/10.1007/s11095-009-0045-6
Notes: Tirzepatide and semaglutide contain no free Cys (no disulfides), removing this pathway entirely.

1.3 Backbone Hydrolysis

Claim: Direct hydrolysis of peptide bonds is slow at pH 5–7 (half-life of years for most bonds at 25 °C). The exception is Asp-Xaa, particularly Asp-Pro (8–20× more labile than average at pH 2, ~10× at pH 4.5) and Asp-Gly (half-life 4.2 h at pH 2.0 / 60 °C).
Confidence: C1.
Source: Asp-Pro / Asp-Gly comparison — https://pubs.rsc.org/en/content/articlelanding/2020/cp/c9cp05240b ; mAb fragmentation review — https://www.tandfonline.com/doi/full/10.4161/mabs.3.3.15608
Notes: Mechanism is intramolecular: the Asp side-chain carboxyl attacks the following amide, generating a succinimide that hydrolyzes the backbone. Hot during acidic stress (HPLC mobile phase containing TFA at 60 °C will fragment Asp-Pro peptides — confounder for stability-indicating assays).

1.4 Aggregation & Fibril Formation

Claim: Semaglutide self-assembles into oligomeric micelles (~7-mer) plus a minor population of needle-shaped fibrils in PBS-like buffer. Aggregation is pH-sensitive near the pI (5.4): the highest extent of degradation is at pH 4.5–5.5; the commercial formulation is held >pH 7.0 (Ozempic disodium phosphate, pH 7.4).
Confidence: C1.
Source: Hamley et al., Biomacromolecules 2025 — https://pubs.acs.org/doi/10.1021/acs.biomac.5c00342 ; Malgave et al., J Peptide Sci 2025 — https://onlinelibrary.wiley.com/doi/10.1002/psc.70039
Notes: Lipidation (C18 diacid linker via γ-Glu/2×OEG in semaglutide) increases oligomer size and stability vs. parent GLP-1, but the same amphipathicity is what predisposes to fibrillation under stress (heat, shear, low-pH excursions). Liraglutide (C16 monoacid) fibrillates under mechanical shaking, not just pH.

Claim: Aggregation kinetics are typically non-Arrhenius — there is often a nucleation lag followed by autocatalytic growth, so accelerated-temperature studies can mis-predict shelf life either direction.
Confidence: C2.
Source: Wang W., Int J Pharm 1999 — https://pubmed.ncbi.nlm.nih.gov/10460913/
Notes: This is the single biggest reason ICH Q1A accelerated extrapolation can fail for peptides.

1.5 Diketopiperazine (DKP) Formation

Claim: N-terminal DKP cleavage releases the first two residues as a cyclic dipeptide; rate is governed by (a) the unprotonated fraction of the N-terminal amine (rises with pH) and (b) cis-isomerism of the Xaa1-Pro2 bond when Pro is in position 2.
Confidence: C1.
Source: Battersby et al., Int J Pept Protein Res 1994 (hGH N-terminus) — https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1399-3011.1994.tb00163.x ; tirzepatide SPPS DKP study — https://pmc.ncbi.nlm.nih.gov/articles/PMC9773959/
Notes: Xaa-Pro-Xaa N-termini are the highest-risk motif. Tirzepatide begins Tyr-Aib-Glu-Gly-Thr…; the Aib (α-aminoisobutyric acid) at position 2 sterically blocks DKP and was chosen partly for that reason. Semaglutide begins His-Aib-Glu-Gly-Thr… with the same Aib protection.

1.6 Surface Adsorption

Claim: Adsorptive loss to glass, polypropylene, and silicone is negligible above ~1 mg/mL but becomes significant below ~100 µg/mL; in the µg/mL range, delivered concentration can drop to 5–50 % of intended (insulin IV infusion data).
Confidence: C1/C2.
Source: Insulin adsorption review — https://pmc.ncbi.nlm.nih.gov/articles/PMC8258516/ ; West Pharma white paper — https://www.westpharma.com/blog/2018/august/protein-adsorption-to-primary-container-systems-why-is-it-important
Notes: GLP-1 analogues are typically formulated at 1–10 mg/mL, so adsorption is minor in the vial itself, but it matters for any downstream dilution (e.g., for IV trials). Polysorbate 80 at 0.02–0.1 % saturates the air-liquid and solid-liquid interfaces and is the standard mitigation.

1.7 β-Elimination of Disulfides

Claim: Disulfides undergo β-elimination at pH > 8 or 37 °C/pH 7–9, generating dehydroalanine + persulfide; dehydroalanine cross-links to Lys (lysinoalanine) or another Cys (lanthionine), giving covalent aggregates.
Confidence: C1.
Source: Florence (1980); Volkin & Klibanov work — https://pubmed.ncbi.nlm.nih.gov/21142/
Notes: Not relevant to semaglutide/tirzepatide/retatrutide (no disulfides). Relevant to oxytocin, octreotide, somatostatin analogues, BPC-157 has no disulfide either.

1.8 Racemization

Claim: Racemization of L → D is slow at neutral pH and 25 °C (centuries for first 10 % in flexible small peptides), accelerates at alkaline pH via the 5(4H)-oxazolone intermediate, and is catalyzed by free thiols (which can arise from disulfide β-elimination — creating a coupled degradation cascade).
Confidence: C1.
Source: Smith & Sivakua, JACS 1983 — https://pubs.acs.org/doi/10.1021/ja00759a064 ; BioProcess Int review — https://www.bioprocessintl.com/formulation/stability-considerations-for-biopharmaceuticals-overview-of-protein-and-peptide-degradation-pathways
Notes: Practically irrelevant on the timescale of a multi-week reconstituted peptide vial; theoretically relevant for multi-year solid-state shelf life.

2. Temperature Dependence: Quantitative Framework

2.1 Arrhenius and Q10

Claim: The Arrhenius equation k = A·exp(–Ea/RT) holds for individual chemical degradation pathways (deamidation, oxidation, hydrolysis) over the 4–40 °C range for most peptides; it fails for aggregation when nucleation is the rate-limiting step.
Confidence: C2.
Source: Wang 1999; ICH Q1A(R2) — https://www.ikev.org/haber/stabilite/kitap/29%201.1%20Stability%20Workshop%20ICH%20Q1AR2%20C.pdf
Notes: Q10 = exp(10·Ea/(RT²)). For Ea = 13 kcal/mol at T ≈ 300 K, Q10 ≈ 2.0; for Ea ≈ 20 kcal/mol, Q10 ≈ 3.0; for Ea ≈ 25 kcal/mol, Q10 ≈ 3.9.

Claim: Typical pharmaceutical degradation Ea is ~98.6 kJ/mol (23.6 kcal/mol) averaged across small-molecule and peptide hydrolytic processes; peptide-specific deamidation runs lower (~13–17 kcal/mol); oxytocin deamidation in formulation studies showed Ea up to 116.3 kJ/mol (27.8 kcal/mol) at pH 4.5.
Confidence: C1.
Source: Waterman et al., MedChemComm 2011 — https://pubs.rsc.org/en/content/articlelanding/2011/md/c0md00214c ; oxytocin study — https://link.springer.com/article/10.1007/s11095-009-9878-2
Notes: Peptide Ea is generally lower than small-molecule Ea, meaning peptide degradation is less temperature-sensitive in absolute Q10 terms than a typical small molecule — but starts from a much higher baseline rate.

2.2 Practical Extrapolation Table

Using Ea = 13 kcal/mol (deamidation-dominated peptide, Q10 ≈ 2.0):
- If rate at 4 °C (277 K) = 1 % loss/week →
- 22 °C (295 K): rate × ~3.4 = ~3.4 %/week
- 25 °C (298 K): rate × ~4.0 = ~4 %/week
- 37 °C (310 K): rate × ~9.6 = ~9.6 %/week
- 40 °C (313 K): rate × ~11.5 = ~11.5 %/week

Using Ea = 20 kcal/mol (oxidation-dominated, Q10 ≈ 3.0):
- 4 → 22 °C: ×7.3
- 4 → 37 °C: ×35
- 4 → 40 °C: ×46

Claim: ICH Q1A(R2) accepts 6 months at 40 °C / 75 % RH as predictive of 24 months at 25 °C / 60 % RH only when the degradation mechanism is constant across the temperature range.
Confidence: C1.
Source: ICH Q1A(R2) — https://www.ikev.org/haber/stabilite/kitap/29%201.1%20Stability%20Workshop%20ICH%20Q1AR2%20C.pdf
Notes: For aggregating peptides this assumption frequently breaks — heat accelerates fibrillation disproportionately above ~35 °C.

2.3 Empirical GLP-1 Data

Claim: Semaglutide approved labelling: 56 days at ≤30 °C (in-use); tirzepatide approved labelling: 21 days at ≤30 °C; both 2-year refrigerated shelf life at 2–8 °C.
Confidence: C2 (labelling) / C4 (compounding-pharmacy sources).
Source: Storage-guide summaries — https://www.fellahealth.com/guide/does-glp-1-have-to-be-refrigerated ; https://zappyhealth.com/all-articles/compounded-tirzepatide-storage-tips/
Notes: ~2.7× difference in room-temperature window plausibly reflects (a) tirzepatide's higher oxidation susceptibility at pH 5 (Daicel impurity analysis — https://www.daicelpharmastandards.com/blog/degradation-pathways-and-impurity-formation-in-glp-1-therapeutics/) and (b) larger number of degradation peaks observed in tirzepatide forced-degradation HPLC (17–18 peaks across acid/oxidative/thermal stress).

3. Sequence and Structural Predictors of Stability

Claim: Lipidation (e.g., C18 diacid in semaglutide, C20 diacid in tirzepatide) stabilizes against in-vivo proteolysis (albumin binding shields the peptide) but promotes self-assembly in solution; net effect on chemical stability is favorable because oligomerization buries reactive side chains.
Confidence: C1.
Source: Hamley et al. 2025 — https://pubs.acs.org/doi/10.1021/acs.biomac.5c00342
Notes: This is why Aib substitutions (which kill DPP-4 cleavage) and the fatty-acid linker do not visibly destabilize the molecule in the vial.

Claim: Aib (α-aminoisobutyric acid) at position 2 of GLP-1 analogues simultaneously confers DPP-4 resistance, helical propensity, and DKP resistance (the gem-dimethyl quaternary α-carbon prevents the cyclization geometry).
Confidence: C1.
Source: Tirzepatide SPPS DKP study — https://pmc.ncbi.nlm.nih.gov/articles/PMC9773959/
Notes: Retatrutide also has Aib at position 2, same rationale.

Claim: Cyclic peptides degrade ~10–100× more slowly than linear analogues in solution because both N-terminal DKP and C-terminal hydrolysis are mechanistically blocked.
Confidence: C2.
Source: Manning et al. 2010 update — https://link.springer.com/article/10.1007/s11095-009-0045-6
Notes: Not directly relevant to GLP-1 family (all linear with lipid linkers) but explains octreotide/cyclosporin shelf lives.

4. Formulation Factors

4.1 pH

Claim: Most peptides show a U-shaped degradation-rate vs. pH curve with minimum near pH 4–6 for hydrolysis/deamidation balance. Aggregating peptides shift this: semaglutide is most stable at pH 7.4–7.6, ~1 pH unit above its pI (5.4), to maximize same-charge repulsion.
Confidence: C1.
Source: Malgave et al. 2025 — https://onlinelibrary.wiley.com/doi/10.1002/psc.70039
Notes: Generalization: pick pH ≥1 unit from pI for self-aggregating peptides; pH 5–7 for non-aggregators.

4.2 Buffer Selection

Claim: Phosphate accelerates deamidation 2–3× vs. Tris or acetate at matched pH/ionic strength because HPO₄²⁻ acts as a general base catalyst for the succinimide step.
Confidence: C1.
Source: Robinson 2001; Tomizawa & Yamada — https://pmc.ncbi.nlm.nih.gov/articles/PMC5343963/
Notes: Semaglutide uses disodium phosphate (the trade-off is buffer capacity at pH 7.4); histidine and acetate are gentler alternatives.

4.3 Excipients

Claim: Polysorbate 80 (0.02–0.1 %) blocks interface-driven aggregation (air-liquid, vial wall) but autoxidizes to peroxides that can drive Met/Cys oxidation — its own degradation cascade.
Confidence: C2.
Source: Polysorbate review — https://www.ejpps.online/post/a-comprehensive-review-on-the-stability-and-degradation-of-polysorbates-in-biopharmaceuticals
Notes: This is the well-known polysorbate paradox.

Claim: Mannitol (lyo bulking agent, isotonifier) is inert in solution. Trehalose protects by water replacement + vitrification in the dried state; minimal effect in pure aqueous formulations.
Confidence: C2.
Source: https://biolongevitylabs.com/research/mannitol-vs-trehalose-peptide-excipients/ ; https://pmc.ncbi.nlm.nih.gov/articles/PMC9412841/
Notes: Semaglutide formulation contains propylene glycol + phenol + disodium phosphate dihydrate; tirzepatide contains sodium phosphate dibasic heptahydrate + sodium chloride.

4.4 Preservatives (incl. Benzyl Alcohol in BAC Water)

Claim: Benzyl alcohol at 0.9 % (the BAC-water concentration) is bacteriostatic for ≤28 days and is generally compatible with most therapeutic peptides; documented exception is oxytocin, where benzyl alcohol accelerates degradation.
Confidence: C2/C4.
Source: Oxytocin stability — https://link.springer.com/article/10.1007/s11095-009-9878-2 ; usage guides — https://uaepeptides.com/peptide-reconstitution-guide/
Notes: Mechanism for oxytocin: benzyl alcohol promotes intermolecular thiol-disulfide exchange and may catalyze deamidation. For GLP-1 analogues (no Cys, no free thiols), benzyl alcohol's main risk is being a substrate for peroxide-mediated oxidation that consumes formulation oxygen — neutral to slightly stabilizing in practice.

Claim: m-Cresol and phenol (insulin preservatives) shift insulin's hexamer-monomer equilibrium and stabilize the storage form; phenol is also part of the semaglutide commercial formulation as preservative.
Confidence: C2.
Source: Wang 1999 — https://pubmed.ncbi.nlm.nih.gov/10460913/
Notes: Phenol is a mild antioxidant — modest protective effect against Met oxidation.

4.5 Container/Headspace

Claim: N₂ headspace lowers Met oxidation rate ~10× vs. air; amber glass attenuates UV-B/A enough to slow Trp/Tyr photodegradation by >90 %. Borosilicate glass leaches ppb-level Fe³⁺/Al³⁺ that catalyzes oxidation; cyclic-olefin polymer vials reduce this.
Confidence: C2.
Source: Manning et al. 2010 — https://link.springer.com/article/10.1007/s11095-009-0045-6
Notes: Practical implication: when transferring reconstituted peptide between vials, minimize air exposure (don't shake), use amber tube if storing >2 weeks, and consider chelator addition (EDTA 0.01–0.05 % is GRAS).

5. Framework Applied to GLP-1 Analogues

For an Aib²-stabilized, lipidated, lysine-conjugated GLP-1 family peptide (semaglutide, tirzepatide, retatrutide):

1. DKP at N-terminus: blocked by Aib² → not rate-limiting.
2. DPP-4 / proteolysis: blocked by Aib² + albumin binding → not relevant in vial.
3. Deamidation: modest — sequences contain Asn at position 8 (semaglutide) but flanked by Aib/Glu (slow context). Predicted half-life of order weeks-to-months at 37 °C; days-to-weeks of meaningful loss at 4 °C is reasonable.
4. Oxidation: the dominant chemical pathway. Tirzepatide forced-degradation shows the most peaks under oxidative stress; both peptides contain Trp (W25 in GLP-1 numbering) and oxidation-sensitive His.
5. Aggregation/fibrillation: the dominant physical pathway, gated by pH proximity to pI (5.4 for sema). Mechanical stress (shaking, transport vibration) and low-pH excursions are the biggest practical risks.
6. Surface adsorption: negligible at commercial 1–10 mg/mL; non-trivial only for highly diluted research preparations <100 µg/mL.

The Q10 ≈ 2–3 rule means a vial that loses ~1 %/week at 4 °C will lose ~3–10 %/week at 22 °C and ~10–30 %/week at 37 °C; this matches the empirical 21–56-day in-use windows on the approved labels.

6. Key Sources for Further Reading

• Manning, Patel & Borchardt. Pharm Res 6:903 (1989) — foundational review.
• Manning et al. Pharm Res 27:544 (2010) — 20-year update — https://link.springer.com/article/10.1007/s11095-009-0045-6
• Wang W. Int J Pharm 185:129 (1999) — https://pubmed.ncbi.nlm.nih.gov/10460913/
• Robinson NE & Robinson AB. PNAS 98:944 / 4367 (2001) — deamidation database — https://pmc.ncbi.nlm.nih.gov/articles/PMC60067/
• Schöneich, "Chemical Pathways of Peptide Degradation" series (Pharm Res, parts I–IX, 1989–2005).
• ICH Q1A(R2) Stability Testing Guideline — https://www.ikev.org/haber/stabilite/kitap/29%201.1%20Stability%20Workshop%20ICH%20Q1AR2%20C.pdf
• Hamley et al., Biomacromolecules 2025 — semaglutide aggregation — https://pubs.acs.org/doi/10.1021/acs.biomac.5c00342
• Malgave et al., J Peptide Sci 2025 — semaglutide preformulation — https://onlinelibrary.wiley.com/doi/10.1002/psc.70039
• Daicel Pharma — GLP-1 degradation pathways summary — https://www.daicelpharmastandards.com/blog/degradation-pathways-and-impurity-formation-in-glp-1-therapeutics/

Community Evidence: Reconstituted GLP-1 Peptide Shelf Life

Scope: Grey-market biohacker community practice — Reddit was inaccessible to direct fetching, but GLP1Forum.com (a sister forum that draws heavily from the Reddit retatrutide/peptides community) yielded extensive indexed quotes. Confidence levels per claim. Date: 2026-05-23.

Note on Reddit access: Direct fetch to reddit.com returned blocked/403. Findings here triangulate via WebSearch results that surface Reddit and forum content and via direct fetches of secondary sources. Where a claim is cited "via search summary," the underlying quote was returned by indexed search of the forum thread but I could not load the thread itself to verify upvotes or exact phrasing — flagged as such.

1. Headline Distribution of Opinion

Almost no one claims >3 months. The 28-day floor is hospital/BAC-manufacturer convention; the 6-12 week ceiling is what biohackers actually do.

2. The Janoshik Anchor — the most-cited authority

The community's most-cited stability number traces to Peter Magic / "Janoshik Analytical" (a Czech third-party peptide testing lab popular with grey-market vendors).

Claim: Reconstituted retatrutide in BAC water lasts 6-8 weeks in the fridge with negligible degradation; unconstituted (lyophilized) lasts 2 years in fridge / 10+ years at -20 °C freezer.
Confidence: C3 (third-party lab claim, often paraphrased, not a published assay)
Source: GLP-1 Forum thread "Reconstituted Reta - what's the latest on shelf-life?" — https://glp1forum.com/threads/reconstituted-reta-whats-the-latest-on-shelf-life.8635/
Notes: Paraphrased across multiple threads. Janoshik's founder reportedly told this story in a YouTube interview that the forum cites.

Claim: Janoshik's own anecdote — "forgot a box of peptide in his garage for 10 years and when he tested it, it had degraded only 4%."
Confidence: C4 (uncorroborated anecdote from a vendor-adjacent figure, but widely repeated)
Source: "Peptide Myths Busted: Janoshik Founder Sets the Record Straight" — https://glp1forum.com/threads/peptide-myths-busted-janoshik-founder-sets-the-record-straight.5811/
Notes: This thread is the community's go-to anti-fragility post. It explicitly argues peptides are "good for years in the fridge and decades in the freezer."

Claim: Reconstituted frozen reta degrades ~14% after 30-45 days; reconstituted refrigerated reta degrades only 3-5% over 45 days.
Confidence: C3 (lab-attributed numbers; freeze damage thesis widely accepted)
Source: Cited in "Can Reconstituted Reta be Re-Aliqouted and Frozen" — https://glp1forum.com/threads/can-reconstituted-reta-be-re-aliqouted-and-frozen.5844/
Notes: This is the single most actionable data point in the community: freezing reconstituted reta is worse than refrigerating it. Contradicts amateur intuition.

3. BAC Water vs Sterile Water — community consensus

Claim: BAC water (0.9% benzyl alcohol) is preservative and lets you use a vial across 28+ days; sterile/saline water makes the vial effectively single-use (24h limit) because there is no antimicrobial preservative.
Confidence: C2 (USP/manufacturer-backed)
Source: Multiple — Wittmer Clinic semaglutide mixing guide; GLP3 Planner retatrutide guide (https://glp3planner.com/resources/retatrutide-storage-stability)

Claim (contrarian, from Janoshik): "In Europe, simple sterile water or saline is preferred to bacteriostatic water, which is often unreliable from cheap sources and not inherently necessary for peptide preservation, only for sterility."
Confidence: C4 (single source, expert opinion)
Source: "Peptide Myths Busted: Janoshik Founder Sets the Record Straight" — https://glp1forum.com/threads/peptide-myths-busted-janoshik-founder-sets-the-record-straight.5811/
Notes: Important nuance — BAC's role is microbial, not chemical-stability. The peptide itself doesn't care about benzyl alcohol.

4. Temperature Excursions — what users actually do

Claim: A single overnight at room temperature "makes no difference"; brief excursions are routinely shrugged off.
Confidence: C4 (consensus anecdotal)
Source: Multiple GLP-1 Forum threads including "Reta Temp" (https://glp1forum.com/threads/reta-temp.12719/) and "Can I store my bac water and reta at room temperature?" (https://glp1forum.com/threads/can-i-store-my-bac-water-and-reta-at-room-temperature.5986/)
Notes: Forum advice: if you plan to use the vial within ~15 days after the excursion, do not worry.

Claim: Lyophilized reta stored at fluctuating 10-30 °C for 4 weeks resulted in no effect at all even at 8 mg dose ("cooked reta") — same user found hunger uncontrolled.
Confidence: C4 (single-user but mechanistically plausible)
Source: GLP-1 Forum "Cooked reta and stop start" — https://glp1forum.com/threads/cooked-reta-and-stop-start.9858/
Notes: The most cited cautionary tale. Drives the "do not store above 30 °C for extended periods" rule.

Brand-pen reference (vendor-side, not biohacker):
- Zepbound (tirzepatide pen): up to 86 °F / 30 °C for 21 days per Lilly.
- Wegovy (semaglutide pen): same range for 28 days per Novo Nordisk.
- Compounded versions: pharmacies tell users to refrigerate always.

5. Visual Signs of Degradation — actually-reported observations

Claim: Cold-induced cloudiness in reconstituted retatrutide that clears within ~20 min at room temperature is not degradation — it's reversible cold-induced protein aggregation.
Confidence: C3 (mechanistically supported, frequently reported)
Source: GLP-1 Forum "Cloudy Reta a week after Reconstitution" — https://glp1forum.com/threads/cloudy-reta-a-week-after-reconstitution.11441/ and Evolutionary.org "Cloudy Retatrutide" — https://www.evolutionary.org/forums/threads/cloudy-retatrutide.107732/ (direct fetch 403, content via search summary)
Notes: "Crystal clear" right after reconstitution; "cloudy when pulled from the fridge a week later at 37°F. The cloudiness cleared at room temperature within about 20 minutes." Verdict in thread: cold-induced solubility behavior, not contamination.

Claim: True degradation signs are non-reversible cloudiness, particulate floaters, yellowing beyond pale-yellow, or odor — discard immediately.
Confidence: C2 (universal community + vendor agreement)
Source: GLP3 Planner; cross-referenced with Eli Lilly / Novo Nordisk pen labels.

Claim: Some peptides gel after reconstitution (not common in GLP-1s but reported); cagrilintide and semaglutide noted as more prone to aggregation at high concentrations.
Confidence: C3
Source: "Why do some peptides turn into a gel-like state after being reconstituted with BAC water?" — https://glp1forum.com/threads/why-do-some-peptides-turn-into-a-gel-like-state-after-being-reconstituted-with-bac-water.8572/

6. Freezing Reconstituted Peptide — community verdict: DON'T

Claim: "Janoshik recommended against freezing [reconstituted] and advised keeping it in the fridge instead."
Confidence: C3 (lab opinion + observed data above)
Source: "Can Reconstituted Reta be Re-Aliqouted and Frozen" — https://glp1forum.com/threads/can-reconstituted-reta-be-re-aliqouted-and-frozen.5844/

Claim: "Ice crystals damage peptide structure" / "30-50%+ potency loss" if frozen reconstituted — quoted in several vendor guides; community internalizes this even though the 14% Janoshik figure is the harder data point.
Confidence: C3
Source: Peptides.wiki / SeekPeptides storage guides (vendor) + GLP-1 Forum repetition.

Counter-claim (re-aliquoting strategy): Some users do aliquot fresh reconstituted reta into small frozen single-dose vials, accepting ~14% loss in exchange for avoiding 8+ weeks of fridge use of a multi-puncture vial. The dominant view is to skip this and just refrigerate.

7. Retatrutide Specifically: More Fragile or Less?

Claim: Tirzepatide is more forgiving than retatrutide for unideal storage conditions. "People are more reluctant to freeze reta once reconstituted, compared to tirzepatide."
Confidence: C4 (community lore, but consistent across threads)
Source: GLP-1 Forum search summaries (https://glp1forum.com/threads/how-long-can-i-store-reta-in-my-fridge.11880/ and related)
Notes: Reta has the cold-cloudiness quirk that sema and tirz don't visibly exhibit. Reta is also newer, so the community is more cautious.

Claim: Reta-specific quirk — temperature mismatch during reconstitution (cold powder + warm BAC water, or vice-versa) and fast water addition both cause cloudiness on the spot.
Confidence: C3
Source: "Cloudy Reta a week after Reconstitution" — https://glp1forum.com/threads/cloudy-reta-a-week-after-reconstitution.11441/
Notes: Recommended technique: let powder warm to room temp first; add BAC water down the side of the vial slowly; do not shake.

Claim: "Reta - No Effect" / "Reta, still no effect" threads exist (https://glp1forum.com/threads/reta-no-effect.9296/, https://glp1forum.com/threads/reta-still-no-effect.8541/) — but these usually trace to suspected counterfeit/underdosed product, not in-fridge degradation. The mechanism in community lore: bad vendor, not bad fridge.

8. Efficacy Loss From Old Vials — how common?

Claim: True efficacy loss from a properly-refrigerated, BAC-water reconstituted vial within 8 weeks is rare and small — most "stopped working" reports are attributed to (a) tolerance/plateau on the drug itself, (b) bad vendor, or (c) temperature excursion, not fridge time.
Confidence: C4
Source: Reta plateau thread (https://glp1forum.com/threads/retatrutide-plateau-adaptation-or-resistance-to-reta.11660/) — community attributes plateaus to physiology, not to peptide decay.

Claim: "Once any peptide solution is mixed, it will degrade somewhat, but if refrigerated the effect is typically insignificant at around 1-2% over a few months."
Confidence: C4 (forum claim, no citation)
Source: GLP-1 Forum via search summary of "Reta Temp" / "How long can I store reta in my fridge"
Notes: This is the community's working assumption — and it's the basis for the popular "3 months in the fridge" practice.

9. Shake vs. No-Shake — Janoshik debunk

Claim: Shaking the vial vigorously does not damage peptide. Janoshik tested a "shaken aggressively" vial against a "carefully handled" vial of rHGH and found no difference in lab assay.
Confidence: C3 (single lab demo, but a credible one)
Source: "How fragile are peptides?" — https://glp1forum.com/threads/how-fragile-are-peptides.838/ and "Peptide Myths Busted" — https://glp1forum.com/threads/peptide-myths-busted-janoshik-founder-sets-the-record-straight.5811/
Notes: Contradicts vendor pamphlets that say "never shake." Community considers swirl-vs-shake debate mostly bunk; cosmetic at best.

10. Vendor / Lab Claims (flag: marketing)

11. Inaccessible-but-Cited Reddit threads (for follow-up)

These surfaced in indexed results but could not be loaded directly. Listed for the next pass if Reddit access becomes available:

• r/retatrutide — storage/shelf-life threads (multiple, no direct URLs surfaced)
• r/peptides — sticky/wiki (would need direct visit; not indexed)
• r/Tirzepatidecompound — BUD discussions (search summaries vague)
• r/Mounjaro — overnight room-temp threads (Facebook group surfaced instead)
• r/Semaglutide — degradation reports (only research-paper hits surfaced)
• moreplatesmoredates.com — no peptide storage guide surfaced despite explicit search

The GLP1Forum.com platform consistently surfaced — it's effectively the indexed peptide community for this topic, and many of its users cross-post from r/retatrutide.

12. Bottom-line Community Practice (synthesized)

The single highest-impact actionable claim: Refrigerated reconstituted GLP-1 peptide is stable enough that the 28-day "rule" is conservative by 2-3x; the real risk is temperature excursion above 30 °C or vial contamination, not fridge time. Cited degradation at 45 days refrigerated is 3-5% (Janoshik via GLP-1 Forum).

The single highest-impact caveat: All quantitative claims trace back to a small handful of Janoshik-attributed numbers that are not published in a peer-reviewed venue. C3 ceiling on these.